MedTrace Logo

Effects of Arzoxifene on Bone Mass and the Uterus

NCT00085956 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2007-03-09

No results posted yet for this study

Summary

The purposes of this study are to determine:

* The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women.
* The effects of arzoxifene on the uterus (womb) in postmenopausal women.
* The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density.
* The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk.
* The safety of arzoxifene and any side effects that might be associated with its use.

Conditions

  • Postmenopausal Bone Loss

Interventions

DRUG

Arzoxifene

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00085956 on ClinicalTrials.gov